CTI announced that is has opened an office in Geel, Belgium.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that is has opened an office in Geel, Belgium. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Belgium SPRL. This is the company’s sixth new office opened this year, with additional new offices expected to be announced in the next several months.
“We have had CTI employees in Belgium for the past several years working on behalf of our pharmaceutical and biotechnology clients, but it felt like it was time to formalize an office in the country,” according to Patrick Earley, Vice President, International. “Belgium is desirable for clinical trials due to innovative regulatory agencies, as well as excellent academic centers and researchers, leading to rapid study start up timelines and high enrollment at sites.”
CTI has been working for over fifteen years in the drug development industry in North America, Europe, South America, and Pac-Asia, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.